Drug intelligence / Profile preview

NLP-787

Development stage: Unknown
Lead developer: NovaLead Pharma
Modality: Small Molecules

Overview

NLP-787 is a small molecule drug developed by NovaLead Pharma Pvt Ltd. It is being investigated for the treatment of skin and musculoskeletal diseases, with its primary indication being eczema. The precise mechanism of action has not been defined or disclosed in public sources as of the latest updates. The drug remains at the discovery stage and has not advanced to clinical trials or regulatory approval[1][2][5].

Beyond the preview

Go deeper on NLP-787.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NLP-787.

Explore the full profile